FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064751521> ?p ?o ?g. }

• W2064751521 endingPage "91" @default.
• W2064751521 startingPage "82" @default.
• W2064751521 abstract "The experimentally induced TS/A murine mammary carcinoma is poorly immunogenic and mainly infiltrated by antigen-presenting cells (APCs), namely macrophages and immature dendritic cells (DCs). Human (h) and mouse (m) lymphocyte activation gene-3 (LAG-3 or CD233) is a physiological MHC class II ligand and powerful APC activator. A gene transfer approach has revealed its anti-tumour activity in this model: hLAG-3 was more effective than mLAG-3. To obtain a clearer picture of the immunoregulatory mechanisms associated with the rejection dynamics of h- and m-LAG-3 transfectants, immunohistochemistry and confocal microscopy analyses of TS/A-hLAG-3, TS/A-mLAG-3, and control TS/A-pc tumours were performed. The immune events elicited by mLAG-3 and m-interleukin (IL)-12 were also compared, since their rejection kinetics were quite similar, and LAG-3 enables IL-12 production by macrophages and DCs. Both the TS/A-h- and, to a lesser extent, the m-LAG-3 rejection areas were characterized by an impressive recruitment of APCs, granulocytes, NK cells, CD4+ T lymphocytes and CD8+ IFNgamma-expressing cells. In both cases, infiltration by APCs was accompanied by strong CD80 and CD86 expression and macrophage nitric oxide (NO) synthase up-regulation. Distinct expression of IL-12 and CXCL9 was also found, especially in the draining lymph nodes. T lymphocytes and CD86-expressing APCs were significantly prevalent in both the TS/A-h- and the m-LAG-3 compared with the TS/A-mIL-12 rejection area. Production of IFNgamma, TNFalpha and IL1beta, and chemokines, namely CXCL5, CXCL9, CXCL10, CXCL11, CCL5, and CCL2, by infiltrating leukocytes and signs of defective neovascularization were detected in tumours expressing h-LAG-3-, m-LAG-3-, and m-IL-12. However, IFNgamma, CCL2, and CCL5 production prevailed in the TS/A-hLAG-3 rejection area. Taken together, these results indicate that LAG-3 expression by engineered tumour cells efficiently promotes intra-tumoural recruitment, activation, and Th1 commitment of APCs, and leads to a wide intra-tumoural influx of non-specific and specific reactive cells, and the release of immunoregulatory and cytotoxic mediators. Many of LAG-3's anti-tumour activities are shared with IL-12." @default.
• W2064751521 created "2016-06-24" @default.
• W2064751521 creator A5000626730 @default.
• W2064751521 creator A5013226213 @default.
• W2064751521 creator A5021131686 @default.
• W2064751521 creator A5044272723 @default.
• W2064751521 creator A5050414562 @default.
• W2064751521 creator A5059397407 @default.
• W2064751521 creator A5066513017 @default.
• W2064751521 creator A5086188675 @default.
• W2064751521 creator A5090467586 @default.
• W2064751521 date "2005-01-01" @default.
• W2064751521 modified "2023-10-03" @default.
• W2064751521 title "Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway" @default.
• W2064751521 cites W1518549789 @default.
• W2064751521 cites W1531857501 @default.
• W2064751521 cites W1578871315 @default.
• W2064751521 cites W1606078320 @default.
• W2064751521 cites W1606763503 @default.
• W2064751521 cites W1964623882 @default.
• W2064751521 cites W1968113197 @default.
• W2064751521 cites W1971444570 @default.
• W2064751521 cites W1976648310 @default.
• W2064751521 cites W1976899534 @default.
• W2064751521 cites W1988105476 @default.
• W2064751521 cites W1992249154 @default.
• W2064751521 cites W2000924812 @default.
• W2064751521 cites W2006187748 @default.
• W2064751521 cites W2017193054 @default.
• W2064751521 cites W2027700151 @default.
• W2064751521 cites W2030995912 @default.
• W2064751521 cites W2046844548 @default.
• W2064751521 cites W2051379819 @default.
• W2064751521 cites W2051715995 @default.
• W2064751521 cites W2059043426 @default.
• W2064751521 cites W2080559907 @default.
• W2064751521 cites W2108221597 @default.
• W2064751521 cites W2122689603 @default.
• W2064751521 cites W2128417084 @default.
• W2064751521 cites W2134403422 @default.
• W2064751521 cites W2136754957 @default.
• W2064751521 cites W2148740102 @default.
• W2064751521 cites W2170879352 @default.
• W2064751521 cites W4230693812 @default.
• W2064751521 cites W4241363665 @default.
• W2064751521 cites W4313347784 @default.
• W2064751521 doi "https://doi.org/10.1002/path.1679" @default.
• W2064751521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15586367" @default.
• W2064751521 hasPublicationYear "2005" @default.
• W2064751521 type Work @default.
• W2064751521 sameAs 2064751521 @default.
• W2064751521 citedByCount "36" @default.
• W2064751521 countsByYear W20647515212012 @default.
• W2064751521 countsByYear W20647515212015 @default.
• W2064751521 countsByYear W20647515212016 @default.
• W2064751521 countsByYear W20647515212017 @default.
• W2064751521 countsByYear W20647515212018 @default.
• W2064751521 countsByYear W20647515212019 @default.
• W2064751521 countsByYear W20647515212020 @default.
• W2064751521 countsByYear W20647515212021 @default.
• W2064751521 countsByYear W20647515212022 @default.
• W2064751521 crossrefType "journal-article" @default.
• W2064751521 hasAuthorship W2064751521A5000626730 @default.
• W2064751521 hasAuthorship W2064751521A5013226213 @default.
• W2064751521 hasAuthorship W2064751521A5021131686 @default.
• W2064751521 hasAuthorship W2064751521A5044272723 @default.
• W2064751521 hasAuthorship W2064751521A5050414562 @default.
• W2064751521 hasAuthorship W2064751521A5059397407 @default.
• W2064751521 hasAuthorship W2064751521A5066513017 @default.
• W2064751521 hasAuthorship W2064751521A5086188675 @default.
• W2064751521 hasAuthorship W2064751521A5090467586 @default.
• W2064751521 hasConcept C104317684 @default.
• W2064751521 hasConcept C127716648 @default.
• W2064751521 hasConcept C154317977 @default.
• W2064751521 hasConcept C167672396 @default.
• W2064751521 hasConcept C185592680 @default.
• W2064751521 hasConcept C202751555 @default.
• W2064751521 hasConcept C203014093 @default.
• W2064751521 hasConcept C207936829 @default.
• W2064751521 hasConcept C2776090121 @default.
• W2064751521 hasConcept C2777761686 @default.
• W2064751521 hasConcept C2778297628 @default.
• W2064751521 hasConcept C2778814158 @default.
• W2064751521 hasConcept C2779919695 @default.
• W2064751521 hasConcept C2781101188 @default.
• W2064751521 hasConcept C39347974 @default.
• W2064751521 hasConcept C55493867 @default.
• W2064751521 hasConcept C67662055 @default.
• W2064751521 hasConcept C86803240 @default.
• W2064751521 hasConcept C8891405 @default.
• W2064751521 hasConcept C95444343 @default.
• W2064751521 hasConceptScore W2064751521C104317684 @default.
• W2064751521 hasConceptScore W2064751521C127716648 @default.
• W2064751521 hasConceptScore W2064751521C154317977 @default.
• W2064751521 hasConceptScore W2064751521C167672396 @default.
• W2064751521 hasConceptScore W2064751521C185592680 @default.
• W2064751521 hasConceptScore W2064751521C202751555 @default.
• W2064751521 hasConceptScore W2064751521C203014093 @default.

• next